These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

662 related articles for article (PubMed ID: 24051998)

  • 41. Change in incidence of clinic visits for all-cause and rotavirus gastroenteritis in young children following the introduction of universal rotavirus vaccination in Israel.
    Muhsen K; Chodick G; Goren S; Anis E; Ziv-Baran T; Shalev V; Cohen D
    Euro Surveill; 2015; 20(42):. PubMed ID: 26538450
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries.
    Giaquinto C; Dominiak-Felden G; Van Damme P; Myint TT; Maldonado YA; Spoulou V; Mast TC; Staat MA
    Hum Vaccin; 2011 Jul; 7(7):734-48. PubMed ID: 21734466
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spotlight on pentavalent rotavirus vaccine (RotaTeq) in the prevention of rotavirus gastroenteritis in Europe.
    Plosker GL
    BioDrugs; 2010 Dec; 24(6):411-4. PubMed ID: 21043548
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost of routine immunization of young children against rotavirus infection with Rotarix versus RotaTeq.
    Weycker D; Sofrygin O; Kemner JE; Pelton SI; Oster G
    Vaccine; 2009 Aug; 27(36):4930-7. PubMed ID: 19555715
    [TBL] [Abstract][Full Text] [Related]  

  • 45. No evidence of an increase in the incidence of norovirus gastroenteritis hospitalizations in young children after the introduction of universal rotavirus immunization in Israel.
    Muhsen K; Kassem E; Rubenstein U; Goren S; Ephros M; Shulman LM; Cohen D
    Hum Vaccin Immunother; 2019; 15(6):1284-1293. PubMed ID: 30945960
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study.
    Lee H; Park SY; Clark A; Debellut F; Pecenka C; Kim DS; Kim HM; Kim JH; Cho H; Kim AY; Lee M; Jung SY; Seong BL; Kang HY
    Vaccine; 2019 Aug; 37(35):4987-4995. PubMed ID: 31326252
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acute gastroenteritis hospitalizations after implementation of universal mass vaccination against rotavirus.
    Kõivumägi K; Toompere K; Soeorg H; Kallas E; Jõgeda EL; Huik K; ; Lutsar I
    Vaccine; 2020 Mar; 38(13):2879-2886. PubMed ID: 32067818
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pentavalent rotavirus vaccine (RotaTeq): a review of its use in the prevention of rotavirus gastroenteritis in Europe.
    Plosker GL
    Drugs; 2010 Jun; 70(9):1165-88. PubMed ID: 20518582
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil.
    Justino MC; Linhares AC; Lanzieri TM; Miranda Y; Mascarenhas JD; Abreu E; Guerra SF; Oliveira AS; da Silva VB; Sanchez N; Meyer N; Shafi F; Ortega-Barria E; Soriano-Gabarró M; Colindres RE
    Pediatr Infect Dis J; 2011 May; 30(5):396-401. PubMed ID: 21150692
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Routine laboratory testing data for surveillance of rotavirus hospitalizations to evaluate the impact of vaccination.
    Patel MM; Tate JE; Selvarangan R; Daskalaki I; Jackson MA; Curns AT; Coffin S; Watson B; Hodinka R; Glass RI; Parashar UD
    Pediatr Infect Dis J; 2007 Oct; 26(10):914-9. PubMed ID: 17901797
    [TBL] [Abstract][Full Text] [Related]  

  • 51. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe.
    Vesikari T; Itzler R; Karvonen A; Korhonen T; Van Damme P; Behre U; Bona G; Gothefors L; Heaton PM; Dallas M; Goveia MG
    Vaccine; 2009 Dec; 28(2):345-51. PubMed ID: 19879226
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of Rotavirus Genotypes in Korea 5 Years after the Introduction of Rotavirus Vaccines.
    Chung JY; Kim MS; Jung TW; Kim SJ; Kang JH; Han SB; Kim SY; Rhim JW; Kim HM; Park JH; Jo DS; Ma SH; Jeong HS; Cheon DS; Kim JH
    J Korean Med Sci; 2015 Oct; 30(10):1471-5. PubMed ID: 26425045
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rotavirus gastroenteritis hospitalization rates and correlation with rotavirus vaccination coverage in Sicily.
    Restivo V; Caracci F; Sannasardo CE; Scarpitta F; Vella C; Ventura G; Tramuto F; Costantino C
    Acta Biomed; 2018 Oct; 89(3):437-442. PubMed ID: 30333453
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessing the impacts of the first year of rotavirus vaccination in the United Kingdom.
    Marlow R; Muir P; Vipond B; Lyttle M; Trotter C; Finn A
    Euro Surveill; 2015; 20(48):30077. PubMed ID: 26675375
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact and Effectiveness of Monovalent Rotavirus Vaccine in Armenian Children.
    Sahakyan G; Grigoryan S; Wasley A; Mosina L; Sargsyan S; Asoyan A; Gevorgyan Z; Kocharyan K; Avagyan T; Lopman B; Vanyan A; Khactatryan S; Parashar UD; Cortese MM
    Clin Infect Dis; 2016 May; 62 Suppl 2():S147-54. PubMed ID: 27059349
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rotavirus disease burden, Nicaragua 2001-2005: defining the potential impact of a rotavirus vaccination program.
    Amador JJ; Vasquez J; Orozco M; Pedreira C; Malespin O; De Oliveira LH; Tate J; Parashar U; Patel M
    Int J Infect Dis; 2010 Jul; 14(7):e592-5. PubMed ID: 20022778
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hospital-based surveillance of rotavirus gastroenteritis in the era of limited vaccine uptake through the private sector.
    Trimis G; Koutsoumbari I; Kottaridi C; Palaiologou N; Assimakopoulou E; Spathis A; Lebessi E; Konstantopoulos A; Kafetzis D; Karakitsos P; Papaevangelou V
    Vaccine; 2011 Oct; 29(43):7292-5. PubMed ID: 21816195
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: a model-based evaluation.
    Fisman DN; Chan CH; Lowcock E; Naus M; Lee V
    Vaccine; 2012 Dec; 30(52):7601-7. PubMed ID: 23107595
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Socioeconomic Impact of the Rotavirus Vaccine in Korea: Comparing the Epidemiologic and Economic Characteristics of Rotavirus Gastroenteritis Before and After the Introduction of Vaccines.
    Cho H; Lee H; Kim DS; Kim HM; Kim JH; Kim AY; Kang HY
    Pediatr Infect Dis J; 2020 May; 39(5):460-465. PubMed ID: 31990891
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reduction in pediatric rotavirus-related hospitalizations after universal rotavirus vaccination in Belgium.
    Raes M; Strens D; Vergison A; Verghote M; Standaert B
    Pediatr Infect Dis J; 2011 Jul; 30(7):e120-5. PubMed ID: 21436757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.